Figure 5
From: Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
PathScan analysis of dual inhibition of the central RTKs and signaling nodes. The dual inhibition-sensitive MDA-MB231 and H1437 cell lines were left untreated (0), treated with 3.3μM ZSTK474, 1 μM CI-1040, or their combination for 24 h and analyzed with the PathScan antibody array assay for the phosphorylation status of 28 central RTKs (bottom 13 rows) and 11 signaling nodes (top five rows). The AKT, S6 and ERK1/2 signals are circled. The whole array target map is available through the manufacturer’s homepage (http://www.cellsignal.com/products/7982.html).